SEC Filing Summary: Trovagene, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. on August 15, 2012. The filing serves to announce the company's financial results for the second quarter ended June 30, 2012. The registrant is a Delaware corporation headquartered in San Diego, California.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were issued in a press release (Exhibit 99.1) but does not reproduce the financial data within the body of the 8-K.
Material Changes
No material changes or comparative financial data versus the prior period are detailed in this specific filing text. The filing references the issuance of a press release containing the results but does not summarize the variances.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 unless specifically incorporated by reference.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing the attached Press Release (Exhibit 99.1), as they are not listed in this summary text.
- Confirm the company name discrepancy: The metadata lists "Cardiff Oncology, Inc.", but the filing is explicitly for "Trovagene, Inc."
- Review the full text of the August 15, 2012 press release for any operational updates or clinical trial milestones not captured in this 8-K header.
- Check subsequent filings to determine if the financial data in the press release was later incorporated by reference into other SEC documents.